Krystal Biotech Inc
NASDAQ:KRYS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
108.01
213.66
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Krystal Biotech Inc
Krystal Biotech Inc
Net Change in Cash
Krystal Biotech Inc
Net Change in Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Change in Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Krystal Biotech Inc
NASDAQ:KRYS
|
Net Change in Cash
$726k
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-65%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Change in Cash
-$6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-17%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Change in Cash
-$669m
|
CAGR 3-Years
57%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Change in Cash
-$25.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-116%
|
CAGR 10-Years
-19%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Change in Cash
-$5.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Change in Cash
-$148.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Krystal Biotech Inc
Glance View
Krystal Biotech Inc. ventures into the complex but promising world of gene therapy, a field that carries the potential to transform how genetic diseases are treated. Founded in 2016, this Pennsylvania-based company focuses on developing and commercializing redosable gene therapies for patients suffering from debilitating skin diseases. Their flagship program, centered on a product called B-VEC, targets dystrophic epidermolysis bullosa (DEB), a rare and severe genetic skin disorder that causes fragile skin prone to blistering. Krystal Biotech leverages a proprietary gene delivery platform, based on herpes simplex virus (HSV-1), to transport corrective copies of genes directly to the affected skin cells, aiming to accelerate healing and dramatically improve patients’ quality of life. In terms of its business model, Krystal Biotech generates revenue primarily by bringing these transformative therapies to market, tapping into unmet medical needs that traditionally lacked effective solutions. By focusing on rare diseases, which often face less competitive pressure, Krystal positions itself in a niche but critical segment of the healthcare market. The company undertakes extensive clinical trials and regulatory processes to ensure its therapies demonstrate safety and efficacy before securing approvals. Additionally, Krystal actively engages with the healthcare ecosystem, including insurers and providers, to facilitate patient access and reimbursement. This strategic pathway not only enables the company to generate revenue but also aligns with its mission of transforming lives through innovative science.
See Also
What is Krystal Biotech Inc's Net Change in Cash?
Net Change in Cash
726k
USD
Based on the financial report for Sep 30, 2024, Krystal Biotech Inc's Net Change in Cash amounts to 726k USD.
What is Krystal Biotech Inc's Net Change in Cash growth rate?
Net Change in Cash CAGR 5Y
-65%
Over the last year, the Net Change in Cash growth was -100%. The average annual Net Change in Cash growth rates for Krystal Biotech Inc have been -44% over the past three years , -65% over the past five years .
You don't have any saved screeners yet
